Jesús G Lugo

Assistant Professor, Hematologist at @KUCancercenter specializing in #Leukemia and #MDS . Former Chief Hematology/Oncology Fellow @EinsteinMed @MontefioreNYC

[Jesús G Lugo @LugoMd]

@mmejia91 Felicidades!

[KU Cancer Center @KUcancercenter]

#ASH25 attendees: Head over to the Valencia Room (W415A) from 2-3:30 pm where lead author Jesus Gonzalez-Lugo is discussing for “Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium.” #KUBloodCancer #AML

[Daniel Peters @DPetersMD]

Happy #ASH2025 week! The🩸MARROW consortium is publishing on #AML. Honored to have been part of the inaugural publication in @BrJHaem ! https://t.co/sbCYgrjmqT

🔑Oral Abstract Session Sat, 12/6 (245-330P)👇
🧬11q23/KMT2A-r AML
🧬MECOM-r AML

📚Great work & great group! #leusm

[Joshua Zeidner MD @LeukDocJZ]

A great way to start ASH week! Our Real World Analysis of CPX-351 in younger & older AML-MR pts now in-print @BrJHaem. Kudos to @DPetersMD who led this analysis from the Marrow Consortium @AkEisfeld @madanatyazan @BKRagonMD @LancetJeff @UNC_Lineberger
https://t.co/Sg1NejnBjo

[Dr. Uma Borate: Professor @beatalleukemia]

Presentation @EHA_Hematology #EHA25 & publication of our Phase 1b Aza+Ven+Revumenib study led by @LeukDocJZ by the Beat AML Consortium by @LLSusa 👇🏾

[KU Cancer Center @KUcancercenter]

Several @KUcancercenter experts contributed to the recently published @ASCO Educational Book article "Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia" ➔ https://t.co/DBN1uHycYd

#CancerResearch #ClinicalTrials #ASCO25 #AML #KUBloodCancer

[Yazan Madanat, MD @madanatyazan]

Beautiful day in #Rotterdam @Visit_NL for the MDS Foundation Meeting #2025 — honored to be here in this stunning city. Great opening by @garciamanero on #HR-MDS and an exciting agenda ahead. Looking forward to an inspiring few days! #MDS25 @MDSFoundation @utswcancer

[Ioannis Mantzaris @YannisMantz]

🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML
demonstrating 85% CR (86% MRD-neg)
@BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC
Eric J. Feldman @MendelGoldfing2
@mkonople @Amitvermamds @aditishasMD @Gritsman_lab
#leusm

https://t.co/tcGDSCQCFD

[Yazan Madanat, MD @madanatyazan]

Honored to present the James D. Cook, M.D. Memorial Lecture on MDS at the @KansasUniv #ASH24 Review. Grateful for the invitation and Dr. @AYACOUB7's inspiring opening remarks. Let the learning begin! 🎊🎊 @UTSWMedCenter @utswcancer

[SWOG Cancer Research Network @SWOG]

#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. https://t.co/tHEbp3R5K6
Co-PI: Tara Lin, MD @KUcancercenter #leusm #AMLsm

[Andres Gomez @GomezDLeonMD]

The success of blinatumomab in first line ALL continues.

The next step is working for global access and equity! Humans with leukemia should not die just because of where they were born.

Read ASH NEWS out now: https://t.co/Um4mMBWuMw #ASH24

[Jesús G Lugo @LugoMd]

Great and varied session about menin inhibitors, bleximenib 33% CRc in R/R MLL and NPM1mut #AMLsm Enzomenib CRc 48% MLL, 47% NPM1, no dose reduction for azoles, 7+3/Zifto 100% CRc! In NPM1 #ASH24 @LeukDocJZ @DrEmmaSearle @Dr_AmerZeidan

[Jesús G Lugo @LugoMd]

Best thing to do during SD #ASH24 eat tacos 🌮 🌮, and best in Tijuana!

[Andres Gomez @GomezDLeonMD]

AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by @LugoMd to clarify the meaning of “hispanic” #ASH24.

Mexicans working together in both sides of the Rio Bravo (Grande)

@NidiaZa07175883 #Leusm

[Jesús G Lugo @LugoMd]

Great presentation @YannisMantz @EinsteinDeptMed presenting on 7+3 and Venetoclax in #AMLsm with CR rates of 80% with 85% MRD negativity #ASH24

[Jesús G Lugo @LugoMd]

First thing I did getting to #ASH24 in San Diego? Getting Tacos 🌮 🌮 in Tacos el gordo, the best!

[Zahra M, PharmD, MBA, BCOP, FHOPA @kczmj]

Next up, @j_snyder0132 presenting #ASH24 poster 2411 on teclistamab in BCMA therapy exposed vs naive in RRMM!

@KUcancercenter @thisisJamesD @Abdallah81MD @NausheenAhmedMD @mumairmushtaq

#oncopharm

[Joshua Zeidner MD @LeukDocJZ]

So proud of @DPetersMD @UNC_Lineberger for a stellar presentation at #ASH24 on outcomes of CPX in younger AML pts w/ MDS mutations. Younger pts w/ AML & MDS mu had better outcomes w/ CPX despite equivalent alloBMT rates. @AkEisfeld @madanatyazan @mjhochman

[Jesús G Lugo @LugoMd]

@mmejia91 @jaimegzz353 Que nos pongan un stand en ASH con tacos estaría bien.

[Jesús G Lugo @LugoMd]

@jaimegzz353 Cómo se llaman los tacos donde hay caramelos? Que está bien buenos!!

[Jesús G Lugo @LugoMd]

@jaimegzz353 El coronado, vayan a los tacos el gordo